Rhenovia Opens Biosimulation Platform for Collaborative CNS Drug Discovery and Development Projects
News May 01, 2009
Rhenovia Pharma SAS, a biopharmaceutical company specialized in the development and optimization of drugs for Alzheimer's and other diseases of the brain, announces today that it is offering its first biosimulation platform for use in collaborative projects to optimize drugs targeting diseases of the central nervous system.
The Rhenovia platform is being made available as part of the company's RHEDDOS program. Developed over the last three years the platform, RHENOMS SYNAPSE, is one of the most advanced systems that exploit the complexity of biology systems and the multifactorial nature of brain diseases.
The platform models synaptic transmission and simulates brain functions, such as learning and memory, and their pathological states. It works by integrating elementary models of molecular processes taking place at individual synapses and incorporating them into a global model of synaptic transmission.
This unique technology developed by Rhenovia allows testing the pharmacological properties of a molecule based on its actions on physiological functions. It does this by taking account of how a molecule interacts dynamically with the whole CNS. It can handle multiple facets of a disease by searching for combinations of drugs that act simultaneously on multiple targets, and by identifying optimal combinations of two or more drug principles that together provide synergistic pharmacological effects.
Rhenovia's platform can be applied in discovery, preclinical and clinical stages - and to drugs already on the market. Typical applications are boosting the activity of drug candidates already in clinical trials, extending the life cycle of a drug, identifying the best molecular targets for drugs under development, and evaluating effective drug combinations.
One of the most promising application areas is extending the life of blockbuster drugs that are reaching the end of their patent protection. Using the Rhenovia platform, pharmaceutical and biotechnology companies will be able to modify or combine the drug to produce a new patentable entity.
The company has already carried out pilot projects with Sanofi-Aventis, which have provided successful proof of concept on the pharmaceutical company's molecules in Phase I-II for cognitive deficits, and the company expects to announce further projects that use its platform. RHEDDOS is available in various configurations to suit customer needs, from answering simple questions to joint projects involving upfront payments, milestones and royalties.
In recent years, numerous studies have shown that people who don't get enough sleep are at greater risk of stroke and heart attack. A study found that people who sleep fewer than 7 hours per night have lower blood levels of three physiological regulators, or microRNAs, which influence gene expression and play a key role in maintaining vascular health.